Gout flares are commonly treated with colchicine, which can provoke GI side effects, particularly diarrhea. The Acute Gout Flare Receiving Colchicine Evaluation (AGREE) trial investigated the efficacy ...

May 7, 2010 — The US Food and Drug Administration (FDA) has issued new dosing guidelines for colchicine (Colcrys tablets; URL Pharma, Inc) when used with protease inhibitors in HIV patients. According ...

Colchicine may be used with caution to manage flare-ups of crystal-induced arthritis among patients with severe chronic kidney disease, with dosage modifications and careful monitoring required.

The LoDoCo2 trial found a reduced cardiovascular risk with low-dose colchicine in patients with chronic coronary disease. In this substudy, attenuation of pericoronary adipose tissue did not differ ...

Please provide your email address to receive an email when new articles are posted on . In patients with chronic coronary disease, adding low-dose colchicine to optimal medical therapy reduced risk ...

Colchicine, a widely available gout medication, has received FDA approval to be used in low dose to prevent cardiovascular events in patients with proven coronary disease. The approval to use low dose ...

An Australian-Dutch trial led by Perth GenesisCare cardiologists, Professor Peter Thompson and Dr Mark Nidorf, in collaboration with the Dutch Network for Cardiovascular Research (WCN) in the ...

A widely used, inexpensive gout drug could reduce heart attacks and strokes in people with cardiovascular disease, according to a new review. The work appears in the Cochrane Database of Systematic ...

Jan Cornel and C. Michael Gibson Discuss: LoDoCo2 Low-Dose Colchicine in Coronary Disease. Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is ...

The open-label, prospective study (GRECCO-19) assessed the effect of treatment with low-dose colchicine on cardiac and inflammatory biomarkers as well as clinical outcomes. Colchicine could ...

(UPDATED) Colchicine taken at a daily dose of 0.5 mg safely reduces cardiovascular events among patients with chronic coronary disease, according to data from the placebo-controlled randomized LoDoCo2 ...

Please provide your email address to receive an email when new articles are posted on . High-dose oral colchicine during reperfusion and for 5 days failed to reduce infarct size in patients with STEMI ...